Boehringer Asks DC Circ. To Stay Aggrenox Doc Production
By Eric Kroh ( April 12, 2017, 3:39 PM EDT) -- Boehringer Ingelheim Pharmaceuticals Inc. has told the D.C. Circuit it would be irreparably harmed if it were forced to give the Federal Trade Commission documents on a 2008 patent dispute settlement over the drug Aggrenox and has asked the court to stay an order to produce the documents pending appeal....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.